Phase I trial of YHI-1003 plus Bortezomib and Dexamethasone

Phase I trial of YHI-1003 Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients Previously Treated with Bortezomib

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221706

Enrollment

Registered

2012-01-30

Start date

2012-01-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed Multiple Myeloma previously treated with Bortezomib

Interventions

investigational material(s) Generic name etc : YHI-1003 INN of investigational material : Perifosine Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigationa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Patients were previously diagnosed with multiple myeloma (2)Patients must have relapsed after their last dose of bortezomib-based therapy (3)Patients must have received 1 to 4-myeloma therapies (4)ECOG performance status (PS) :0-2

Exclusion criteria

Exclusion criteria: (1)Patients with uncontrolled intercurrent illness (2)Female patients who are pregnant or lactating (3)Patients with non-secretory multiple myeloma

Design outcomes

Primary

Measure	Time frame
safety CTCAE v3.0	—

Secondary

Measure	Time frame
efficacy and pharmacokinetic profile	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026